269078-79-7 Usage
Uses
Used in Pharmaceutical Industry:
(R,S)-FMOC-3-AMINO-3-(BIPHENYL)-PROPIONIC ACID is used as a non-natural amino acid building block for peptide synthesis, specifically in the development of novel drugs. The unique structural features of (R,S)-FMOC-3-AMINO-3-(BIPHENYL)-PROPIONIC ACID allow for the creation of peptides with tailored properties, potentially leading to more effective therapeutic agents.
Used in Materials Science:
In the field of materials science, (R,S)-FMOC-3-AMINO-3-(BIPHENYL)-PROPIONIC ACID is used as a building block for the design and synthesis of advanced materials with specific properties. The steric bulk and hydrophobicity introduced by the biphenyl group can be exploited to create materials with enhanced performance characteristics, such as improved stability or selectivity in various applications.
Used in Research and Development:
(R,S)-FMOC-3-AMINO-3-(BIPHENYL)-PROPIONIC ACID is also utilized in research and development settings, where it serves as a valuable tool for exploring the structure-activity relationships of peptides and other biomolecules. Its unique properties make it an attractive candidate for studying the effects of structural modifications on biological activity and function.
Check Digit Verification of cas no
The CAS Registry Mumber 269078-79-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,9,0,7 and 8 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 269078-79:
(8*2)+(7*6)+(6*9)+(5*0)+(4*7)+(3*8)+(2*7)+(1*9)=187
187 % 10 = 7
So 269078-79-7 is a valid CAS Registry Number.
269078-79-7Relevant academic research and scientific papers
Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective αvβ3 integrin antagonists
Sulyok,Gibson,Goodman,H?lzemann,Wiesner,Kessler
, p. 1938 - 1950 (2007/10/03)
The solid-phase synthesis of a low molecular weight RGD mimetic library is described. Activities of the compounds in inhibiting the interaction of ligands, vitronectin and fibrinogen, with isolated immobilized integrins αvβ3 and αIIbβ3 were determined in a screening assay. Highly active and selective nonpeptide αvβ3 integrin antagonists with regard to orally bioavailability were developed, based on the aza-glycine containing lead compound 1. An important variation is the substitution of the aspartic amide of 1 by an aromatic residue. Furthermore, different guanidine mimetics have been incorporated to improve the pharmacokinetic profile. Exchange of the β-amino acid NH by a methylene moiety in one set of RGD mimetics leads to the azacarba analogue compounds representing a novel peptidomimetic approach, which should increase the metabolic stability.
